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Thyrotrophin receptor antibodies (TRAb) exist as stimulating or blocking antibodies in the serum (neutral TRAb have been
identiﬁed recently). The clinical features of GD occur when stimulating TRAb predominate. But the relationship of TRAb to
clinical phenotype and outcome is not clear when current assay methods are used. Therefore no consensus exists about its
utility in diagnosing and predicting outcome in GD. The most commonly used TRAb assays, measure thyroid binding inhibiting
immunoglobulins (TBII or “receptor assays”) and don’t diﬀerentiate between stimulating and blocking antibodies. However, the
more expensive, technically demanding and less freely available “biological assays” diﬀerentiate between them by their ability
to stimulate cyclic AMP or failure to do so. Failure to diﬀerentiate between TRAb types and its heterogeneous molecular and
functional properties has limited TBII use to GD diagnosis and diﬀerentiating from other forms of thyrotoxicosis. The current
2nd-3rd generation receptor assays are highly sensitive and speciﬁc when used for this purpose. TRAb assays should also be done
in appropriate pregnant women. Current data do not support its use in outcome prediction as there is a signiﬁcant variability of
assay methodology, population characteristics and study design in published data, resulting in a lack of consensus.
1.Introduction
The immunopathogenesis of Graves’ disease (GD) is a story
thatcontinuestoevolve.GDisuniqueamongstautoimmune
endocrine diseases as the underlying immune perturbation
results in thyroid stimulation rather than its functional
or structural inhibition. The contribution of genetic (MHC,
CTLA-4, and PTPN22) and environmental inﬂuences
(smoking, stress, drugs, micronutrients) to the aetiology
of GD has been described extensively [1–6]. This complex
genetic/environmental interaction results in the production
of Thyrotrophin Receptor Antibodies (TRAb) which stimu-
late the TSH receptor (TSHR) and are the proximate cause of
GD.Theirprecise role in the extrathyroidalmanifestations of
GD is currently being investigated [7].
The earliest description of a thyroid stimulator in GD
was by Adams and Purves in 1956 [8]. The discovery of this
“long-acting thyroid stimulator (LATS)” led to further at-
tempts to characterize it [9]. The target antigen for LATS
was the TSHR [10], and research showed these “thyroid
stimulators” in GD were in fact autoantibodies to the TSHR;
thatis,TRAb.Thecomplexnatureoftheinteractionbetween
TSHR and TRAb has been elegantly demonstrated using
advanced techniques, and the molecular and crystalline
structure of TRAb has been described in detail [11–14]. It
would seem intuitive therefore that measurement of TRAb,
the proximate cause of GD and so intimately involved in its
pathogenesis, would assist in its diagnosis and management.
However, neither contention is consistently borne out in
clinical practice. The relationship between TRAb measured
usingcurrentlyavailableassaysandGDiscomplexandneeds
to be understood by clinicians if they are to be correctly
interpreted in clinical practice.
Current assays detect TRAb in 95-96% of subjects with
GD although only some can demonstrate their functional
characteristics [15]. However, there is no consensus about
its role in diagnosing and managing GD, and its utility in
predicting outcome. The inherent functional properties of
TRAb,thevariabilityinstudydesign,andassaymethodology
have contributed to this uncertainty.2 Journal of Thyroid Research
Table 1: A comparison of TBII and biological assays.
TBII assays Biological assays
Advantages
Freely available commercially
Diﬀerentiate between stimulating and blocking activities of TRAb Relatively cheap
Easy to perform
Sensitive 2nd-3rd generation
assays available
Disadvantages
Do not diﬀerentiate between
stimulating and blocking
activities of TRAb
Most are technically complex and time consuming
Lack absolute correlation with
clinical phenotype
Relatively expensive
No correlation with severity of
illness
Lack predictive value for GD
outcome
TBII are easy to perform, cheap and are highly sensitive. They remain the preferred assay method of choice in clinical practice. Bioassays have the ability
to diﬀerentiate between stimulating and blocking TRAb, but the utility of this property in day-to-day clinical practice is unclear. Furthermore, they require
greater technical expertise to perform and currently are more expensive.
2. The Structure of TRAb and Their Interaction
withTSHRinGD
TRAb are heterogeneous in both molecular structure and
biological activity with a propensity to change during the
course of the disease. They may stimulate the TSHR (thyroid
stimulating antibodies-TSAb) or block its activity (thyroid
blocking antibodies-TBAb) [16]. The clinical phenotype is
thus determined by the balance between their opposing
actions-thyrotoxicosis when TSAb predominate, and hypo-
thyroidism when TBAb predominate. Neutral TRAb have
also been isolated recently and their role in GD is yet to be
deﬁned [17]. TSAbs probably undergo aﬃnity maturation
and bind TSHR with high aﬃnity, although details are not
accuratelyknown[18,19].Anewclassiﬁcationhasbeenpro-
posed for TRAb based on their ability to stimulate or block
both classical cyclic AMP (cAMP) and nonclassical non-
cAMP signalling pathways. This classiﬁcation is functionally
more accurate and intellectually more attractive [16].
The TSHR is a G protein-coupled receptor and has a
molecular structure consistent with this. The extracellular
component consists of a Leucine-rich repeat domain (LRD)
and a hinge region (HR), which links to the 7 domain
transmembrane and intracellular components. The increas-
ingly important role and the structure and function of
the HR are currently being deﬁned [20, 21]. There have
been major recent studies of the synthesis, post translational
modiﬁcation, shedding of the α-subunit and the eﬀect of the
unbound α-subunit on the TSHR [22–25]. The α-subunit
appears to be the primary autoantigen for TRAb formation
[23, 26].
TRAb,incommonwith TSH,bind tothe concavesurface
of the LRD. Recent crystallization studies using the TSHR
stimulating human monoclonal antibody M-22 have shown
the importance of several residues on this concave surface
to the binding process [27] which seemed to be speciﬁc
to this antibody [13]. These residues may not be speciﬁc
for native TSH signalling. After binding to the TSHR, TRAb
stimulate cAMP-dependent signal transduction (and also
non-cAMP-dependent signalling pathways) resulting ulti-
mately in increased thyroid hormone secretion [28]. The
clinical features of GD are thus produced when TSAb pre-
dominate. Predominant TBAb have the opposite eﬀect.
3. Measuring TRAb
3.1. Assay Methodology and Sensitivity. There are two cur-
rently available methods for measuring TRAb [29].
(1) “Receptor assays” using I125 labelled TSH are freely
available commercially for clinical use.
(2) “Bioassays” using cultured cells, which measure
cAMP production as an indicator of TSHR stimu-
lation or inhibition, are still most often used in a
research setting (Table 1).
3.1.1. Receptor Assays. Receptor assays measure “thyroid-
binding inhibiting immunoglobulins” (TBIIs); that is, anti-
bodies that block binding of TSH to an in vitro TSHR
preparation and do not therefore diﬀerentiate between TSAb
and TBAb in serum samples. Some who do not advocate
routine testing of TRAb in GD insist that this is of minor
consequenceasclinicalandbiochemicalfeatureswillidentify
functional characteristics of the predominant TRAb in a
patient with GD. The lack of correlation between TRAb
in these assays and the clinical and biochemical severity of
GD and its outcome may indeed be related to this inability
to diﬀerentiate between the functional properties of TRAb.
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every patient. These assays also have wide intermethod vari-
ability. It has been estimated that the interassay coeﬃcient
of variation between various commercially available assays is
15.2–21.6% [30]. They are commercially freely available and
are easy to perform (Table 1).
While ﬁrst-generation TBII assays using porcine cells
and bovine labelled TSH had a sensitivity of only 50–80%
[31], second-generation assays using recombinant human
TSHR are said to be 90–99% sensitive and 95–100% speciﬁc
[32–34]. Third-generation assays using human monoclonal
TSHR stimulating antibodies are said to be even better
[35] with improved sensitivities (97%) compared to second
generation assays (94%) in one study [36].
There are still a minority of individuals who have GD
who remain TRAb negative even when modern TBII assays
are used. They usually have mild disease, smaller goitres,
and minimal RAI uptake on scintigraphy [37]. In a recent
study only 1.4% of an untreated group of thyrotoxic patients
were in this group when a third-generation assay was used
[38]. It is speculated that they have intrathyroidal TRAb pro-
duction which does not spill over to the circulation, or that
even third-generation TBII assays are too insensitive. Fully
automated TBII assays are now available and should improve
their use [39].
3.1.2. Biological Assays. Biological assays in contrast mea-
sure the ability of TRAb to stimulate or inhibit TSHR
activity. They measure the production of cAMP when sera-
containing TRAb are exposed to TSHR on cell preparations
such as FRTL-5 or CHO [40, 41]. Therefore, they are able to
diﬀerentiate between TSAb and TBAb. However, their sensi-
tivity at predicting GD recurrence is still surprisingly poor
as some studies indicate [42]. This may relate to inherent
properties of TRAb (e.g., antibodies with both blocking and
stimulating activities, very similar receptor-binding charac-
teristics and aﬃnity for the TSHR) or to antibodies that
interfere with these assays that make results diﬃcult to inter-
pret. More recent bioassays using a luciferase reporter gene
on cell lines expressing the TSHR are technically less de-
manding and more rapidly done [43, 44].
Assays utilising modiﬁed TSHR, substituting some
amino acid residues from the luteinizing hormone receptor
(LHR), have produced encouraging results. These chimaeric
TSHR-containing assay systems, for instance using the Mc4
TSHR where amino acid residues 262–368 of the human
wild type receptor have been replaced by residues 262–334
of the rat LHR, seem to perform well under experimental
conditions [45, 46].
Biologicalassaysarecurrentlylimitedtoresearchinmany
centres. Although they provide information about the func-
tional status of TRAb, their use has been restricted because
of expense, and technical expertise and time required to
perform them. Furthermore, the current utility of TBII as-
says in association with clinical and biochemical features to
predict the functional status of TRAb in GD confers on them
anadvantageoverbiologicalassays.However,withadvancing
technology some of the above disadvantages should be
overcome [26].
3.2. TRAb Assays and Speciﬁcity. Current TRAb assays lack
speciﬁcity and may be positive in other thyroid disease.
Recent studies have shown that a signiﬁcant minority with
painless thyroiditis (9.2%) and subacute thyroiditis (6.7%),
hypothyroidism (9%) and multinodular goitre (17.2%) is
TRAb positive using receptor assays [36, 52]. The inability of
current assays to functionally deﬁne TRAb may account for
this lack of speciﬁcity.
4. TRAb in the Diagnosisof Thyrotoxic States
4.1. Establishing a Diagnosis of GD and Diﬀerentiating from
Other Causes of Thyrotoxicosis. Some argue that TRAb assays
are not necessary to diagnose GD and for its diﬀerential
diagnosis from other causes of thyrotoxicosis. If clinical
symptoms and signs are nonspeciﬁc, they advocate the use
of radioiodine (RAI) scintigraphy to diﬀerentiate GD from
other thyrotoxic states [53]. In some centres about 20%
remained of “indeterminate origin” even after RAI scintig-
raphy [54, 55], despite a retrospective cost eﬀectiveness
analysis comparing ultrasound to radioiodine scintigraphy
in GD, which found a high sensitivity (97.4%) and speciﬁcity
(98.8%) for RAI with equally good positive and negative pre-
dictive values [56]. Some argue that assays for other antibod-
ies such as thyroid peroxidase antibodies (TPOAbs), present
only in about 80% of GD but which are easier to perform
and freely and more cheaply available, could be used instead
of TRAb. TPOAb has a low sensitivity and speciﬁcity in this
context and therefore is not very helpful in our opinion.
Thus RAI uptake scans and TPOAb assays are inadequate for
routineclinicaluseforthediﬀerentialdiagnosisofthyrotoxic
states.
GD is diﬃcult to diagnose in the minority of patients
where goitre, overt clinical features, and GO are absent. The
proponents of TRAb agree that the availability of sensitive
and easy to perform, comparatively cheap assays should
make TRAb an essential tool in the diagnostic work-up. Its
high sensitivity ensures thatvirtuallyallsubjects withGD are
picked up. This is important from a practical point of view in
centres where ﬁrst line therapy for GD and other thyrotoxic
states diﬀers. Most clinicians treat GD initially with thion-
amides,beforegivingRAItherapyforarecurrence[57].They
also treat toxic nodular disease (almost all TRAb negative)
with RAI as ﬁrst line therapy (usually after making them
euthyroid with thionamides) [58]. The use of TRAb would
therefore help this decision-making process at an early stage.
There is also an economic argument for using relatively
cheap TRAb assays without using more expensive and cum-
bersome thyroid scintigraphy. In centres where TRAb assays
have been established as routine and are cheaper to do, this
diﬀerential in expense is even greater. The current use of
TRAb in diagnosing GD seems to be governed by tradition,
expense, and the availability of suitable assays.
5.SpecialSituations
5.1. Pregnancy. GD is responsible for nearly 85% of the
0.1–0.4% of pregnancies that are complicated by hyperthy-
roidism [59, 60]. Transplacental passage of TRAb causes4 Journal of Thyroid Research
foetal or neonatal thyrotoxicosis in 1–5% of pregnancies in
women with current or past GD [61]. In the majority of
pregnant women, TRAb levels begin to decline at around 20
weeks of gestation because of gestational immune modula-
tion; the immune milieu is consistent with the Th2 paradigm
during pregnancy and the important roles of hormones and
regulatory T cells in this process are not within the scope of
this paper [62]. The persistence of high levels of TRAb in the
third trimester (measured between 22–26 weeks) increases
risk to the foetus and indicates the need for close monitoring
in association with obstetricians and neonatal specialists.
Some would limit third trimester TRAb testing only to those
mothers who had high titres in the ﬁrst trimester [63].
Although investigators have attempted to correlate TRAb
activity in the mother and neonate with foetal and neonatal
GD, there has been no consensus. Some investigators found
maternal TRAb of >40U/L (using human recombinant
receptor assays) predicted neonatal GD [64]. Japanese inves-
tigators also found that in mothers who had RAI for GD,
TRAblevelsatdeliveryweresigniﬁcantlyhigherinthosewho
delivered infants with neonatal hyperthyroidism compared
to those who did not [65].
The current indications for TRAb testing in pregnancy
a r ea sf o l l o w s[ 66].
(a) Current GD that is, those on thionamide therapy.
(b) Previous radioiodine treatment or surgery for GD
even if euthyroid—2–10% risk of foetal and neonatal
hyperthyroidism.
(c) Previous history of delivering an infant with neonatal
hyperthyroidism.
Subjects who have had previous GD who are in remission
(i.e., on no drug therapy), do not need TRAb testing as their
euthyroid state implies the absence of signiﬁcant levels of
TRAb and therefore no risk to the foetus.
5.2. Immune Reconstitution Syndromes. Modern lymphocyte
depleting agents such as Alemtuzumab (CAMPATH), an
anti-CD52 monoclonal antibody, cause thyroid dysfunction
in a signiﬁcant minority of patients, as many as 30% when
used to treat multiple sclerosis. This immune reconstitution
syndrome may also occur in highly active antiretroviral ther-
apy (HAART) for HIV infection, and bone marrow trans-
plantation from a GD patient [67]. These subjects develop
GD and have detectable TRAb. The mechanisms in Alem-
tuzumab and HAART induced GD seem to be naive CD4 T-
cell expansion, while a graft versus host disease may account
for it in bone marrow recipients [67].
5.3. Orbitopathy. A signiﬁcant proportion of subjects with
GD have clinically evident Graves’ orbitopathy (GO), esti-
matedtobebetween30–50%invariousstudies.Sightthreat-
ening disease occurs in about 5% [68]. The coexistence of
symptoms and signs of GD in the majority of them helps
establish an accurate diagnosis.
However, TRAb assays are mandatory in two circum-
stances: (a) to diagnose the minority where GO occurs as an
isolated disorder without symptoms or signs of GD and (b)
rarely when GO occurs in a hypothyroid patient.
6 .W h atH ap pe nst oT R A bW h e nGDI sT r eat ed ?
Both thionamide therapy and thyroid surgery reduce TRAb
in GD. Thionamides, reduce TRAb primarily by their im-
munomodulatory eﬀects [69, 70]. Surgery does so by
removing the antigen, TSHR [71], and possibly by T and B
lymphocytes apoptosis following high level antigen release
during surgery [25]. The eﬀects of RAI therapy on TRAb
are diﬀerent. An initial rise in TRAb after RAI is followed
by a gradual fall [72]. This initial rise is probably a result
of the release of TSHR antigen following tissue destruction
by RAI. RAI-induced inhibition of T regulatory cells (TReg)
may also contribute [73]. The modulation of TRAb levels
afterthethreemodalitiesoftreatmentdescribedabovewould
suggest that the persistence of TRAb at signiﬁcant levels
would predict further recurrences. However, the story is far
from clear.
7. TRAb inPredictingRecurrencesof GD
The inability of currently available TRAb assays to predict
remission and recurrences of GD remains a great shortcom-
ing in this area. A prediction tool such as TRAb could spare
patients from long and sometimes complicated drug regimes
with potentially serious side eﬀects. The ability to predict the
course of GD would also facilitate early deﬁnitive therapy
with RAI or surgery. Clinical utility at predicting recurrences
was inadequate when using clinical data (goitre volume,
family history of GD, age, gender, smoking, etc.) and bio-
chemical/immunological data (thyroid hormone levels,
TRAb levels, rate of TRAb decline during treatment, etc.)
either singly or in combination.
Early attempts at using TRAb to predict remission of GD
followed a meta-analysis which suggested that the absence
of TRAb after antithyroid drug therapy predicted remission
[47]. But the practical value of this analysis was questionable
and limited as nearly 25% of subjects were misclassiﬁed
[29]. Although large scale, well-powered prospective studies
addressing this question are lacking, a brief examination of
the data from the last decade for the use of TRAb as a
predictor of GD outcome is warranted (Table 2).
The predictive value for TRAb at the assay diagnostic
cutoﬀ value of 1.5 U/L, was low and not of high clinical
utility in an early study published in 2002 [74]. Subsequent
studies attempted to use TRAb thresholds that were higher,
and measured at various points during the course of the
diseasetoimproveitspredictivevalue.Acutoﬀabove10IU/L
at 6 months increased the positive predictive value (PPV) to
97%inonestudy.Butitsnegativepredictivevalue(NPV)was
too low for clinical utility [48]. In a subsequent multicentre
prospectivestudyitwasfoundthatwithin2yearsofstopping
antithyroid drugs (ATD) 49% of 96 patients relapsed. In this
study TRAb at a level of 10 U/L measured at 4 weeks after
stoppingATDhadaPPV0f83%andNPVof62%(speciﬁcity
92%). But TSH also measured at 4 weeks after stopping ATDJournal of Thyroid Research 5
Table 2: Recent clinical studies examining the utility of TRAb assays in predicting GD outcome.
Author (year,
(ref)) Assay (n)S t u d y d e s i g n TRAb cutoﬀ
value % Relapse PPV %
Zimmermann-
Belsing et al.
(2002, [47])
TBII (129)
TRAb assays at diagnosis (122)
and at withdrawal of drugs (129):
median followup 18 months
1.5 U/L 45 49
Quadbeck et al.
(2005, [48]) TBII (96) TRAb assays done 4 weeks after
withdrawal of drugs: followup
for 2 years
1.5 U/L 49 49
10 U/L 83
Quadbeck et al.
(2005, [48]) Bioassay (96) As above 1.5 U/L 49
TSAb-51
Schott et al.
(2007, [49]) TBII (131)
TRAb and TPOAb assays done
4.3 months (mean) after GD
diagnosis
>2a n d<6 U/L 71.8 66.7–90
>6+>5000 100
>6+>500 93.7–96
Cappelli et al.
[2007, [50]] TBII (216) TRAb assays done at diagnosis
and 6 monthly for 120 months
>46.5U/L at
diagnosis or 67.1 52%
>30.7U/L at
6m o n t h s 53.2
Massart et al.
(2009, [51]) TBII (128)
TRAb assays compared after 18
months of treatment: 3-year
followup
0.94–3.2IU/L 48 53–66%
Most recent studies are small and retrospective. They were variable in their study design (e.g., timing of TRAb measurement), assay methodology and TRAb
cutoﬀ values used for analysis, and population characteristics (i.e., geographically disparate). Although there was a high relapse rate (45–71.8%), TRAb assay
by itself had a poor PPV and was a poor predictor of relapse even when diﬀerent cutoﬀ values were used.
had a PPV of 70% and a negative predictive (NPV) value
of 62% for a relapse [49]. Another study made use of the
fact that thyroid peroxidase antibodies (TPOAb) which are
detectable in GD may be used to advantage in combination
with TRAb to increase the predictive value of a relapse.
71.8% of 131 patients with GD relapsed during followup
for between 10–77 months [49]. The PPV for relapse was
100%whenacutoﬀof>5000U/mLwasusedforTPOAband
of >6U / Lf o rT R A b( Table 2). Cappelli and his colleagues
studied 216 patients with GD prospectively for 120 months.
They measured TRAb at diagnosis and every 6 months
thereafter for the duration of the study. TRAb at >46.5U/L
at diagnosis had a PPV of 52% and NPV 0f 77% and
at >30.7U/L at 6 months had a PPV of 53.2% and NPV of
79% for a relapse [50]. A study comparing human mon-
oclonal antibody M22-based TRAb assays and second gen-
eration TRAb assays by Massart and colleagues was not
conclusive either [51]. They measured TRAbafter 18 months
of antithyroid drug treatment and found that the newer
M22-based assays did not improve the predictive value of
relapse. They also commented on high intermethod variabil-
ity.
Deﬁning a consensus is therefore diﬃcult and relates to
severalpertinent issues. The above studies werevariable both
in relation to TRAb assay methodology and study design.
Some studies were retrospective (with all their associated
problems) and some prospective. In the retrospective studies
attempts were made to ﬁnd the most sensitive and speciﬁc
cutoﬀvaluesforTRAbandinoneitsuseincombinationwith
TPOAb was examined. They were also variable in the timing
of TRAb assay, being measured at diagnosis or at diﬀerent
points in the course of their disease. Furthermore, popula-
tiongeneticsandiodinestatusmayalsohaveinﬂuencedthese
studies as they were done in geographically disparate areas.
Therefore, it is our view that till further good quality evi-
dence is forthcoming, TRAb assays seem a rather blunt tool
to predict remission or relapse of GD using current method-
ology.
8. Conclusions and Indications for
TRAb Testing
The clinical utility of TRAb as an important tool in the
diﬀerential diagnosis of thyrotoxic states is established in
our opinion. Although some experts doubt its value in
subjects with typical features of GD, we believe that TRAb
assays should be done in all patients to positively establish a
diagnosis and to help in diﬀerentiating between the various
causes of thyrotoxicosis. Most such experts base their argu-
ment for selective TRAb testing, on the basis of cost, avail-
ability of assays, and traditional practice. However, TRAb
measurements using modern 2nd-3rd generation receptor
assays are increasingly more freely available, quickly done
andcheap(certainlyinhighvolumelaboratories).Theyoﬀer
a greater advantage over TPOAb and thyroid scintigraphy, in
terms of higher sensitivity and speciﬁcity, logistical consider-
ations and cost savings. Furthermore, newer automated 3rd-
generation assays provide excellent sensitivity and speciﬁcity
with high PPV and NPV in subjects with biochemical hyper-
thyroidism[75].Table 3 illustratesthecurrentindicationsfor
performing TRAb tests.6 Journal of Thyroid Research
Table 3: Current indications for TRAb testing.
Indications for TRAb testing
Establishing diagnosis of GD and diﬀerentiating from other thyro-
toxic states
Thyrotoxicosis complicating the Immune reconstitution syndrome
(CAMPATH and HAART)
Euthyroid or unilateral orbitopathy
Orbitopathy with hypothyroidism
Pregnancy in women:
(a) currently on ATD therapy
(b) who have had previous ablative therapy (RAI or surgery)
(c) with previous children who had neonatal thyrotoxicosis
In the ﬁrst trimester and at 22–26 weeks gestation
ThecurrentindicationsforTRAbtestingaredetailedabove.Itsuseislimited
to diagnostic indications. There is no clinical utility of TRAb in predicting
outcome at present.
However, its utility in predicting GD remission/relapse
is still unproven. An ideal prediction tool would be easy
and cheap to measure, sensitive with high PPV and NPV,
when measured early in the course of the disease. The lack
of large, reproducible, well-designed, prospective studies is
a shortcoming in this area of thyroidology. Furthermore,
the variability of study design, TRAb assay methodology,
and target study populations in currently published studies,
added to the variability of intrinsic molecular and functional
characteristicsoftheTRAbmolecule,makethisaspectofGD
management frustrating and lacking in consensus.
References
[1] L. Bartalena, “The dilemma of how to manage Graves’ hyper-
thyroidism in patients with associated orbitopathy,” Journal of
Clinical Endocrinology and Metabolism, vol. 96, no. 3, pp. 592–
599, 2011.
[2] T. J. Smith, “Pathogenesis of Graves’ orbitopathy: a 2010 up-
date,” Journal of Endocrinological Investigation,v o l .3 3 ,n o .6 ,
pp. 414–421, 2010.
[3] Y. Tomer, “Genetic susceptibility to autoimmune thyroid dis-
ease:past,present,andfuture,”Thyroid,vol.20,no.7,pp.715–
725, 2010.
[4] Y. Tomer and A. Huber, “The etiology of autoimmune thyroid
disease: a story of genes and environment,” J o u r n a lo fA u t o i m -
munity, vol. 32, no. 3-4, pp. 231–239, 2009.
[ 5 ]O .J .B r a n da n dS .C .L .G o u g h ,“ G e n e t i c so ft h y r o i da u t o i m -
munity and the role of the TSHR,” Molecular and Cellular
Endocrinology, vol. 322, no. 1-2, pp. 135–143, 2010.
[6] M. L. Tanda, E. Piantanida, A. Lai et al., “Thyroid autoimmu-
nity and environment,” Hormone and Metabolic Research, vol.
41, no. 6, pp. 436–442, 2009.
[7] A. K. Eckstein, K. T. Johnson, M. Thanos, J. Esser, and M.
Ludgate, “Current insights into the pathogenesis of Graves’
orbitopathy,” Hormone and Metabolic Research, vol. 41, no. 6,
pp. 456–464, 2009.
[8] D. D. Adams and H. D. Purves, “Abnormal responses in the
assay of thyrotopin,” Proceedings of the University of Otago
Medical School, vol. 34, pp. 11–20, 1956.
[9] J. P. Kriss, V. Pleshakov, and J. R. Chien, “Isolation and iden-
tiﬁcation of the long acting thyroid stimulator and its relation
to hyperthyroidism and circumscribed pretibial myxoedema,”
The Journal of clinical endocrinology and metabolism, vol. 24,
pp. 1005–1028, 1964.
[10] B. R. Smith and R. Hall, “The thyroid stimulating hormone
receptor and thyroid stimulating antibodies,” Journal of Endo-
crinology, vol. 63, no. 2, pp. 59–60, 1974.
[11] J. Sanders, D. Y. Chirgadze, P. Sanders et al., “Crystal structure
of the TSH receptor in complex with a thyroid-stimulating
autoantibody,” Thyroid, vol. 17, no. 5, pp. 395–410, 2007.
[12] B. Rees Smith, J. Sanders, M. Evans, T. Tagami, and J. Furma-
niak, “TSH receptor—autoantibody interactions,” Hormone
and Metabolic Research, vol. 41, no. 6, pp. 448–455, 2009.
[13] J. Sanders, R. N. Miguel, J. Bolton et al., “Molecular inter-
actions between the TSH receptor and a thyroid-stimulating
monoclonal autoantibody,” Thyroid, vol. 17, no. 8, pp. 699–
706, 2007.
[14] T. Ando, R. Latif, and T. F. Davies, “Antibody-induced modu-
lation of TSH receptor post-translational processing,” Journal
of Endocrinology, vol. 195, no. 1, pp. 179–186, 2007.
[15] K. Z¨ ophel, D. Roggenbuck, and M. Schott, “Clinical review
aboutTRAbassay’shistory,”AutoimmunityReviews,vol.9,no.
10, pp. 695–700, 2010.
[16] K. Michalek, S. A. Morshed, R. Latif, and T. F. Davies, “TSH
receptor autoantibodies,” Autoimmunity Reviews, vol. 9, no. 2,
pp. 113–116, 2009.
[17] S. A. Morshed, T. Ando, R. Latif, and T. F. Davies, “Neutral
antibodies to the TSH receptor are present in Graves’ disease
and regulate selective signaling cascades,” Endocrinology, vol.
151, no. 11, pp. 5537–5549, 2010.
[18] C.D .C.Allen,T .Okada,H.L.T ang,andJ .G.C yst er ,“I maging
of germinal center selection events during aﬃnity matura-
tion,” Science, vol. 315, no. 5811, pp. 528–531, 2007.
[19] C. D. C. Allen, T. Okada, and J. G. Cyster, “Germinal-central
cell organization and cellular dynamics,” Immunity, vol. 27,
no. 2, pp. 190–202, 2007.
[20] S. Mueller, H. Jaeschke, R. G¨ unther, and R. Paschke, “The
hinge region: an important receptor component for GPHR
function,”TrendsinEndocrinologyandMetabolism,vol.21,no.
2, pp. 111–122, 2010.
[21] S. Mueller, M. W. Szkudlinski, J. Schaarschmidt, R. G¨ unther,
R. Paschke, and H. Jaeschke, “Identiﬁcation of novel TSH
interaction sites by systematic binding analysis of the TSHR
hinge region,” Endocrinology, vol. 152, no. 8, pp. 3268–3278,
2011.
[22] G. Vassart, L. Pardo, and S. Costagliola, “A molecular dis-
section of the glycoprotein hormone receptors,” Trends in
Biochemical Sciences, vol. 29, no. 3, pp. 119–126, 2004.
[23] J. Sanders, J. Bolton, P. Sanders et al., “Eﬀects of TSH receptor
mutations on binding and biological activity of monoclonal
antibodies and TSH,” Thyroid, vol. 16, no. 12, pp. 1195–1206,
2006.
[ 2 4 ] C .R .C h e n ,P .P i c h u r i n ,Y .N a g a y a m a ,F .L a t r o f a ,B .R a p o p o r t ,
and S. M. McLachlan, “The thyrotropin receptor autoantigen
in Graves disease is the culprit as well as the victim,” Journal of
Clinical Investigation, vol. 111, no. 12, pp. 1897–1904, 2003.
[25] T. F. Davies, T. Ando, R. Y. Lin, Y. Tomer, and R. Latif, “Thy-
rotropin receptor-associated diseases: from adenomata to
Graves disease,” Journal of Clinical Investigation, vol. 115, no.
8, pp. 1972–1983, 2005.
[26] M. Atger, M. Misrahi, J. Young et al., “Autoantibodies inter-
acting with puriﬁed native thyrotropin receptor,” European
Journal of Biochemistry, vol. 265, no. 3, pp. 1022–1031, 1999.Journal of Thyroid Research 7
[27] J. Sanders, M. Evans, L. D. K. E. Premawardhana et al., “Hu-
man monoclonal thyroid stimulating autoantibody,” Lancet,
vol. 362, no. 9378, pp. 126–128, 2003.
[28] S. D. Lytton and G. J. Kahaly, “Bioassays for TSH-receptor au-
toantibodies: an update,” Autoimmunity Reviews, vol. 10, no.
2, pp. 116–122, 2010.
[29] R. A. Ajjan and A. P. Weetman, “Techniques to quantify TSH
receptor antibodies,” Nature Clinical Practice Endocrinology
and Metabolism, vol. 4, no. 8, pp. 461–468, 2008.
[30] U. Feldt-Rasmussen, “Analytical and clinical performance
goalsfortestingautoantibodiestothyroperoxidase,thyroglob-
ulin,andthyrotropinreceptor,”ClinicalChemistry,vol.42,no.
1, pp. 160–163, 1996.
[31] B. R. Smith and R. Hall, “The thyroid stimulating hormone
receptor and thyroid stimulating antibodies,” Journal of Endo-
crinology, vol. 63, no. 2, pp. 59–60, 1974.
[32] S. Costagliola, N. G. Morgenthaler, R. Hoermann et al., “Sec-
ond generation assay for thyrotropin receptor antibodies has
superior diagnostic sensitivity for Graves’ disease,” Journal of
Clinical Endocrinology and Metabolism,v o l .8 4 ,n o .1 ,p p .9 0 –
97, 1999.
[33] D. Villalta, E. Orunesu, R. Tozzoli et al., “Analytical and diag-
nosticaccuracyof“secondgeneration”assaysforthyrotrophin
receptor antibodies with radioactive and chemiluminescent
tracers,” Journal of Clinical Pathology, vol. 57, no. 4, pp. 378–
382, 2004.
[34] J. Paunkovic and N. Paunkovic, “Does autoantibody-negative
Graves’ disease exist? A second evaluation of the clinical diag-
nosis,” Hormone and Metabolic Research, vol. 38, no. 1, pp. 53–
56, 2006.
[35] B. R. Smith, J. Bolton, S. Young et al., “A new assay for thy-
rotropin receptor autoantibodies,” Thyroid, vol. 14, no. 10, pp.
830–835, 2004.
[36] K.Kamijo,K.Ishikawa,andM.Tanaka,“Clinicalevaluationof
3rd generation assay for thyrotropin receptor antibodies: the
M22-biotin-based ELISA initiated by Smith,” Endocrine Jour-
nal, vol. 52, no. 5, pp. 525–529, 2005.
[37] T. Mukuta, H. Tamai, A. Oshima et al., “Immunological ﬁnd-
ingsandthyroidfunctionofuntreatedGraves’diseasepatients
with undetectable TSH-binding inhibitor immunoglobulin,”
Clinical Endocrinology, vol. 40, no. 2, pp. 215–219, 1994.
[38] A. Theodoraki, G. Jones, J. Parker et al., “Performance of a
third-generation TSH-receptor antibody in a UK clinic,” Clin-
ical Endocrinology, vol. 75, no. 1, pp. 127–133, 2011.
[ 3 9 ]M .S c h o t t ,D .H e r m s e n ,M .B r o e c k e r - P r e u s se ta l . ,“ C l i n i c a l
value of the ﬁrst automated TSH receptor autoantibody assay
for the diagnosis of Graves’ disease (GD): an international
multicentre trial,” Clinical Endocrinology,v o l .7 1 ,n o .4 ,p p .
566–573, 2009.
[40] N. G. Morgenthaler, I. Pompel, G. Aust, J. Seissler, and W. A.
Scherbaum, “Application of a bioassay with CHO cells for the
routine detection of stimulating and blocking autoantibodies
to the TSH-receptor,” Hormone and Metabolic Research, vol.
30, no. 3, pp. 162–168, 1998.
[41] K. Kamijo, A. Nagata, and Y. Sato, “Clinical signiﬁcance of a
sensitive assay for thyroid-stimulating antibodies in Graves’
disease using polyethylene glycol at high concentrations and
porcine thyroid cells,” Endocrine Journal,v o l .4 6 ,n o .3 ,p p .
397–403, 1999.
[42] M. K. Gupta, “Thyrotropin-receptor antibodies in thyroid
diseases:advancesindetectiontechniquesandclinicalapplica-
tions,” Clinica Chimica Acta, vol. 293, no. 1-2, pp. 1–29, 2000.
[43] G. C. J. Hovens, A. M. J. Buiting, M. Karperien et al., “A biolu-
minescence assay for thyrotropin receptor antibodies predicts
serumthyroidhormonelevelsinpatientswithdenovoGraves’
disease,” Clinical Endocrinology, vol. 64, no. 4, pp. 429–435,
2006.
[44] C. Evans, N. G. Morgenthaler, S. Lee et al., “Development of
a luminescent bioassay for thyroid stimulating antibodies,”
Journal of Clinical Endocrinology and Metabolism, vol. 84, no.
1, pp. 374–377, 1999.
[ 4 5 ]S .D .L y t t o n ,K .A .P o n t o ,M .K a n i t z ,N .M a t h e i s ,L .D .K o h n ,
and G. J. Kahaly, “A novel thyroid stimulating immunoglob-
ulin bioassay is a functional indicator of activity and severity
of graves’ orbitopathy,” Journal of Clinical Endocrinology and
Metabolism, vol. 95, no. 5, pp. 2123–2131, 2010.
[ 4 6 ] K .K a m i j o ,H .M u r a y a m a ,T .U z u ,K .T o g a s h i ,a n dG .J .K a h a l y ,
“A novel bioreporter assay for thyrotropin receptor antibodies
using a chimeric thyrotropin receptor (Mc4) is more useful in
diﬀerentiation of graves’ disease from painless thyroiditis than
conventional thyrotropin-stimulating antibody assay using
porcine thyroid cells,” Thyroid, vol. 20, no. 8, pp. 851–856,
2010.
[47] T.Zimmermann-Belsing,B.Nygaard, ˚ A.K.Rasmussen,andU.
Feldt-Rasmussen, “Use of the 2nd generation TRAK human
assay did not improve prediction of relapse after antithyroid
medical therapy of Graves’ disease,” European Journal of
Endocrinology, vol. 146, no. 2, pp. 173–177, 2002.
[48] B. Quadbeck, R. Hoermann, U. Roggenbuck, S. Hahn, K.
Mann, and O. E. Janssen, “Sensitive thyrotropin and thy-
rotropin-receptor antibody determinations one month after
discontinuation of antithyroid drug treatment as predictors of
relapse in Graves’ disease,” Thyroid, vol. 15, no. 9, pp. 1047–
1054, 2005.
[49] M.Schott,A.Eckstein,H.S.Willenberg,T.B.T.Nguyen,N.G.
Morgenthaler, and W. A. Scherbaum, “Improved prediction of
relapse of Graves’ thyrotoxicosis by combined determination
of TSH receptor and thyroperoxidase antibodies,” Hormone
and Metabolic Research, vol. 39, no. 1, pp. 56–61, 2007.
[50] C. Cappelli, E. Gandossi, M. Castellano et al., “Prognostic val-
ue of thyrotropin receptor antibodies (TRAb) in Graves’ dis-
ease: a 120 months prospective study,” Endocrine Journal, vol.
54, no. 5, pp. 713–720, 2007.
[51] C.Massart,J.Gibassier,andM.d’Herbomez,“Clinicalvalueof
M22-based assays for TSH-receptor antibody (TRAb) in the
follow-up of antithyroid drug treated Graves’ disease: com-
parison with the second generation human TRAb assay,” Clin-
ica Chimica Acta, vol. 407, no. 1-2, pp. 62–66, 2009.
[52] I.B.Pedersen,A.Handberg,N.Knudsen,L.Heickendorﬀ,and
P.Laurberg,“Assaysforthyroid-stimulatinghormonereceptor
antibodies employing diﬀerent ligands and ligand partners
may have similar sensitivity and speciﬁcity but are not inter-
changeable,” Thyroid, vol. 20, no. 2, pp. 127–133, 2010.
[53] R. S. Bahn, H. B. Burch, D. S. Cooper et al., “Hyperthyroidism
and other causes of thyrotoxicosis: management guidelines of
the American Thyroid Association and American Association
of Clinical Endocrinologists,” Thyroid, vol. 21, no. 6, pp. 593–
646, 2011.
[54] O. E. Okosieme, D. Chan, S. A. Price, J. H. Lazarus, and L.
D. K. E. Premawardhana, “The utility of radioiodine uptake
and thyroid scintigraphy in the diagnosis and management of
hyperthyroidism,” Clinical Endocrinology, vol. 72, no. 1, pp.
122–127, 2010.
[55] J. A. Franklyn, “What is the role of radioiodine uptake mea-
surement and thyroid scintigraphy in the diagnosis and man-
agement of hyperthyroidism?” Clinical Endocrinology, vol. 72,
no. 1, pp. 11–12, 2010.8 Journal of Thyroid Research
[56] C.Cappelli,I.Pirola,E.DeMartinoetal.,“Theroleofimaging
inGraves’disease:acost-eﬀectivenessanalysis,”EuropeanJour-
nal of Radiology, vol. 65, no. 1, pp. 99–103, 2008.
[ 5 7 ]B .V a i d y a ,G .R .W i l l i a m s ,P .A b r a h a m ,a n dS .H .S .P e a r c e ,
“Radioiodine treatment for benign thyroid disorders: results
ofanationwidesurveyofUKendocrinologists,”ClinicalEndo-
crinology, vol. 68, no. 5, pp. 814–820, 2008.
[58] G. J. Kahaly, L. Bartalena, and L. Heged¨ us, “The American
Thyroid Association/American Association of Clinical Endo-
crinologists guidelines for hyperthyroidism and other causes
ofthyrotoxicosis:aEuropeanperspective,”Thyroid,vol.21,no.
6, pp. 585–591, 2011.
[59] J. H. Mestman, “Hyperthyroidism in pregnancy,” Clinical Ob-
stetrics and Gynecology, vol. 40, no. 1, pp. 45–64, 1997.
[60] G. N. Burrow, “Thyroid function and hyperfunction during
gestation,” Endocrine Reviews, vol. 14, no. 2, pp. 194–202,
1993.
[61] D. Zimmerman, “Fetal and neonatal hyperthyroidism,” Thy-
roid, vol. 9, no. 7, pp. 727–733, 1999.
[62] A. P. Weetman, “Immunity, thyroid function and pregnancy:
molecular mechanisms,” Nature Reviews Endocrinology, vol. 6,
no. 6, pp. 311–318, 2010.
[63] D. Luton, I. Le Gac, E. Vuillard et al., “Management of Graves’
disease during pregnancy: the key role of fetal thyroid gland
monitoring,” Journal of Clinical Endocrinology and Metabo-
lism, vol. 90, no. 11, pp. 6093–6098, 2005.
[64] S. Clavel, A. M. Madec, H. Bornet, P. Deviller, A. Stefanutti,
and J. Orgiazzi, “Anti TSH-receptor antibodies in pregnant
patients with autoimmune thyroid disorder,” British Journal
of Obstetrics and Gynaecology, vol. 97, no. 11, pp. 1003–1008,
1990.
[65] N. Hamada, N. Momotani, N. Ishikawa et al., “Persistent high
TRAb values during pregnancy predict increased risk of ne-
onatal hyperthyroidism following radioiodine therapy for
refractory hyperthyroidism,” Endocrine Journal, vol. 58, no. 1,
pp. 55–58, 2011.
[66] A. Stagnaro-Green, M. Abalovich, E. Alexander et al., “Guide-
lines of the American Thyroid Association for the diagnosis
and management of thyroid disease during pregnancy and
postpartum,” Thyroid, vol. 21, no. 10, pp. 1081–1125, 2011.
[67] A. Weetman, “Immune reconstitution syndrome and the thy-
roid,” Best Practice and Research: Clinical Endocrinology and
Metabolism, vol. 23, no. 6, pp. 693–702, 2009.
[68] K. A. Ponto, M. Kanitz, P. D. Olivo, S. Pitz, N. Pfeiﬀer, and
G. J. Kahaly, “Clinical relevance of thyroid-stimulating im-
munoglobulins in Graves’ ophthalmopathy,” Ophthalmology,
vol. 118, no. 11, pp. 2279–2285, 2011.
[69] A. P. Weetman, “The immunomodulatory eﬀects of antithy-
roid drugs,” Thyroid, vol. 4, no. 2, pp. 145–146, 1994.
[70] C. Carella, G. Mazziotti, F. Sorvillo et al., “Serum thyrotropin
receptor antibodies concentrations in patients with Graves’
disease before, at the end of methimazole treatment, and after
drug withdrawal: Evidence that the activity of thyrotropin
receptor antibody and/or thyroid response modify during the
observationperiod,”Thyroid,vol.16,no.3,pp.295–302,2006.
[71] E.D.Mukhtar,B.R.Smith,andG.A.Pyle,“Relationofthyroid
stimulating immunoglobulins to thyroid function and eﬀects
of surgery, radioiodine, and antithyroid drugs,” Lancet, vol. I,
no. 7909, pp. 713–715, 1975.
[72] P. Laurberg, G. Wallin, L. Tallstedt, M. Abraham-Nordling,
G. Lundell, and O. T¨ orring, “TSH-receptor autoimmunity in
Graves’ disease after therapy with anti-thyroid drugs, surgery,
or radioiodine: a 5-year prospective randomized study,” Euro-
pean Journal of Endocrinology, vol. 158, no. 1, pp. 69–75, 2008.
[ 7 3 ]A .M .M c G r e g o r ,S .M .M c L a c h l a n ,B .R .S m i t h ,a n dR .H a l l ,
“Eﬀect of irradiation on thyroid-autoantibody production,”
Lancet, vol. 2, no. 8140, pp. 442–444, 1979.
[74] M. Schott, N. G. Morgenthaler, R. Fritzen et al., “Levels of
autoantibodies against human TSH receptor predict relapse of
hyperthyroidism in Graves’ disease,” Hormone and Metabolic
Research, vol. 36, no. 2, pp. 92–96, 2004.
[75] N.R.Syme,A.D.Toft,M.Stoddart,andG.J.Beckett,“Clinical
performance of the Roche cobas e411 automated assay sys-
tem for thyrotropin-receptor antibodies for the diagnosis of
Graves’ disease,” Annals of Clinical Biochemistry,v o l .4 8 ,n o .5 ,
pp. 471–473, 2011.